CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 66 enrolled
Drug / intervention
Lycopene 30mg +1 moredrug
Likely dose
Lycopene 30mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01443026
NCT01443026Phase 2Completed
CompareCT.gov

R01 CA90759: The Effects of Lycopene on High Risk Prostatic Tissue

University of Illinois at Chicago·interventional·Posted Sep 29, 2011·Updated Nov 19, 2019

In Brief

A Phase 2 clinical trial evaluating Lycopene 30mg and Placebo for Intraepithelial Prostatic Neoplasia and Prostatic Neoplasms. Completed, enrolled 66 participants across 2 sites.

Detailed Summary

The purpose of this research study is to compare the effects of a lycopene supplement made from tomatoes to a placebo (a capsule with no active ingredients) in men who have abnormal cells in the prostate, but have not yet had cancer detected. This study will allow us to see if taking lycopene for six months leads to favorable changes in abnormal prostate tissue and in chemicals measured in the blood that go along with a higher risk of developing cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIntraepithelial Prostatic Neoplasia, Prostatic Neoplasms
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 29, 2011
Enrollment StartFeb 1, 2006
Primary CompletionApr 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 14.8 years ago

Interventions

Lycopene 30mgdrug

Lycopene 30 mg.

Placebodrug

Placebo